Technical Analysis for BPTH - Bio-Path Holdings Inc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Historical BPTH trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 1.70% | |
Narrow Range Bar | Range Contraction | 1.70% | |
Wide Bands | Range Expansion | 1.70% | |
Oversold Stochastic | Weakness | 1.70% | |
Fell Below 20 DMA | Bearish | 1.39% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | 1.39% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 1.39% | |
Narrow Range Bar | Range Contraction | 1.39% | |
NR7 | Range Contraction | 1.39% | |
Wide Bands | Range Expansion | 1.39% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
Fell Below Previous Day's Low | 10 minutes ago | |
Up 3% | about 1 hour ago | |
Up 2% | about 1 hour ago | |
Up 1% | about 1 hour ago | |
60 Minute Opening Range Breakdown | about 24 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/13/2020
Bio-Path Holdings, Inc., a biotechnology company, focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Its lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers and in preclinical studies for triple negative and inflammatory breast cancers. The company's other drug candidate, Liposomal Bcl-2, is ready for the clinic where it would be evaluated in lymphoma and solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Houston, Texas.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Acid Solid Tumors Lymphoma Breast Cancer Treatment Of Breast Cancer Therapeutic Product Cell Biology Therapeutic Products Oncogenes Apoptosis Blood Cancers Breast Cancers Human Body
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Acid Solid Tumors Lymphoma Breast Cancer Treatment Of Breast Cancer Therapeutic Product Cell Biology Therapeutic Products Oncogenes Apoptosis Blood Cancers Breast Cancers Human Body
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 24.34 |
52 Week Low | 2.9203 |
Average Volume | 2,440,302 |
200-Day Moving Average | 4.64 |
50-Day Moving Average | 5.05 |
20-Day Moving Average | 6.69 |
10-Day Moving Average | 7.08 |
Average True Range | 1.23 |
ADX | 48.04 |
+DI | 55.41 |
-DI | 19.56 |
Chandelier Exit (Long, 3 ATRs ) | 20.65 |
Chandelier Exit (Short, 3 ATRs ) | 7.65 |
Upper Bollinger Band | 10.46 |
Lower Bollinger Band | 2.93 |
Percent B (%b) | 0.47 |
BandWidth | 112.56 |
MACD Line | 0.55 |
MACD Signal Line | 0.77 |
MACD Histogram | -0.2201 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 6.98 | ||||
Resistance 3 (R3) | 7.02 | 6.89 | 6.90 | ||
Resistance 2 (R2) | 6.89 | 6.75 | 6.87 | 6.87 | |
Resistance 1 (R1) | 6.67 | 6.67 | 6.61 | 6.63 | 6.84 |
Pivot Point | 6.54 | 6.54 | 6.50 | 6.52 | 6.54 |
Support 1 (S1) | 6.32 | 6.40 | 6.26 | 6.29 | 6.08 |
Support 2 (S2) | 6.19 | 6.32 | 6.17 | 6.05 | |
Support 3 (S3) | 5.97 | 6.19 | 6.02 | ||
Support 4 (S4) | 5.94 |